David Spellman

Nessuna posizione attualmente

Patrimonio netto: - $ in data 30/04/2024

48 anni

Health Technology

Consumer Services

Precedenti posizioni note di David Spellman

Società	Posizione	Inizio	Fine
AKEBIA THERAPEUTICS, INC.	Comptroller/Controller/Auditor	30/12/2022	23/06/2023
	Direttore Finanziario/CFO	29/06/2020	23/06/2023
	Treasurer	29/06/2020	23/06/2023
Intarcia Therapeutics, Inc. Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA.	Direttore Finanziario/CFO	01/11/2019	29/06/2020
	Corporate Officer/Principal	01/06/2019	01/11/2019
MERSANA THERAPEUTICS, INC.	Direttore Finanziario/CFO	12/03/2018	30/06/2019
VERTEX PHARMACEUTICALS INCORPORATED	Corporate Officer/Principal	-	-

The Wharton School of the University of Pennsylvania

Undergraduate Degree

Distribuzione geografica

Stati Uniti

Posizioni

Director of Finance/CFO	3
Corporate Officer/Principal	2
Undergraduate Degree	1

Settori

Health Technology	5
Consumer Services	2

Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Società quotate in Borsa	3
MERSANA THERAPEUTICS, INC.	Health Technology
VERTEX PHARMACEUTICALS INCORPORATED	Health Technology
AKEBIA THERAPEUTICS, INC.	Health Technology

Aziende private	1
Intarcia Therapeutics, Inc. Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA.	Health Technology

Aziende private

Health Technology